FEATURED COMPANIES
- AbbVie
- Bristol-Myers Squibb
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc.
- Johnson & Johnson
Biologics Global Market Report 2021: COVID-19 Impact and Recovery to 2030 provides the strategists, marketers and senior management with the critical information they need to assess the global biologics market as it emerges from the COVID-19 shut down.
Reasons to Purchase
Description:
Where is the largest and fastest growing market for the biologics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Biologics market global report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider biologics market, and compares it with other markets.
Scope
Markets Covered:
1) By Type: Monoclonal Antibodies (MAbS); Therapeutic Proteins; Vaccines
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies/Drug Stores; Others
3) By Route Of Administration: Oral; Parenteral; Others
4) By Drug Classification: Branded Drugs; Generic Drugs
5) By Mode Of Purchase: Prescription-Based Drugs; Over-The-Counter Drugs
Subsegments Covered: Anti-Cancer MAbS; Immunological MAbS; Anti-Infective Monoclonal Antibodies (MAbs); Neuropharmacological MABS; Cardiovascular and Cerebrovascular MAbS; Other Monoclonal Antibodies (MAbs); Metabolic Disorders Therapeutic Proteins; Cancer Therapeutic Proteins; Cardiovascular Therapeutic Proteins; Immunological Therapeutic Proteins; Other Therapeutic Proteins; Anti-Infective Vaccines; Autoimmunity Vaccines; Other Vaccines
Companies Mentioned: Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Bristol-Myers Squibb; GlaxoSmithKline Plc.; AbbVie
Metrics Covered: Number of Enterprises; Number of Employees
Countries: Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Denmark; Egypt; Finland; France; Germany; Hong Kong; India; Indonesia; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Nigeria; Norway; Peru; Philippines; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Thailand; Turkey; UAE; UK; USA; Venezuela; Vietnam
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, biologics indicators comparison.
Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:
Where is the largest and fastest growing market for the biologics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Biologics market global report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider biologics market, and compares it with other markets.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.
- Market segmentations break down market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
- The biologics market section of the report gives context. It compares the biologics market with other segments of the pharmaceuticals market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, biologics indicators comparison.
Scope
Markets Covered:
1) By Type: Monoclonal Antibodies (MAbS); Therapeutic Proteins; Vaccines
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies/Drug Stores; Others
3) By Route Of Administration: Oral; Parenteral; Others
4) By Drug Classification: Branded Drugs; Generic Drugs
5) By Mode Of Purchase: Prescription-Based Drugs; Over-The-Counter Drugs
Subsegments Covered: Anti-Cancer MAbS; Immunological MAbS; Anti-Infective Monoclonal Antibodies (MAbs); Neuropharmacological MABS; Cardiovascular and Cerebrovascular MAbS; Other Monoclonal Antibodies (MAbs); Metabolic Disorders Therapeutic Proteins; Cancer Therapeutic Proteins; Cardiovascular Therapeutic Proteins; Immunological Therapeutic Proteins; Other Therapeutic Proteins; Anti-Infective Vaccines; Autoimmunity Vaccines; Other Vaccines
Companies Mentioned: Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Bristol-Myers Squibb; GlaxoSmithKline Plc.; AbbVie
Metrics Covered: Number of Enterprises; Number of Employees
Countries: Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Denmark; Egypt; Finland; France; Germany; Hong Kong; India; Indonesia; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Nigeria; Norway; Peru; Philippines; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Thailand; Turkey; UAE; UK; USA; Venezuela; Vietnam
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, biologics indicators comparison.
Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Frequently Asked Questions about the Global Biologics Market
What is the estimated value of the Global Biologics Market?
What is the growth rate of the Global Biologics Market?
What is the forecasted size of the Global Biologics Market?
Who are the key companies in the Global Biologics Market?
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- AbbVie
- Bristol-Myers Squibb
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc.
- Johnson & Johnson
1. Executive Summary2. Report Structure7. Biologics Market Trends and Strategies8. Impact of COVID-19 on Biologics22. Key Mergers and Acquisitions in the Biologics Market26. Copyright and Disclaimer
3. Biologics Market Characteristics
4. Biologics Market Product Analysis
5. Biologics Market Supply Chain
6. Biologics Market Customer Information
9. Biologics Market Size and Growth
10. Biologics Market Regional Analysis
11. Biologics Market Segmentation
12. Biologics Market Segments
13. Biologics Market Metrics
14. Asia-Pacific Biologics Market
15. Western Europe Biologics Market
16. Eastern Europe Biologics Market
17. North America Biologics Market
18. South America Biologics Market
19. Middle East Biologics Market
20. Africa Biologics Market
21. Biologics Market Competitive Landscape
23. Market Background: Pharmaceuticals Market
24. Recommendations
25. Appendix
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- AbbVie
- Bristol-Myers Squibb
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc.
- Johnson & Johnson
Major companies in the biologics market include Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Bristol-Myers Squibb; GlaxoSmithKline Plc. and AbbVie.
The global biologics market is expected to grow from $253.41 billion in 2020 to $268.51 billion in 2021 at a compound annual growth rate (CAGR) of 6%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $420.55 billion in 2025 at a CAGR of 12%.
The biologics market consists of sales of biologics and related services by entities (organizations, sole traders and partnerships) that produce biologics to treat and prevent various microbial diseases and cancers. Biological products include a wide range of products such as vaccines, allergenics, somatic cells, tissues, and recombinant therapeutic proteins. This industry includes establishments that produce products that are composed of sugars, proteins, nucleic acids, and combination of all these substances isolated from humans, animal and microorganisms or produced from biotechnology methods. Specifically, most biologic medicines are developed using recombinant DNA (rDNA) technology. The biologics market is segmented into monoclonal antibodies (mabs); therapeutic proteins; and vaccines.
North America was the largest region in the global biologics market, accounting for 53% of the market in 2020. Asia Pacific was the second largest region accounting for 21% of the global biologics market. Africa was the smallest region in the global biologics market.
The US Food and Drug Administration (FDA) has revised its regulations to eliminate outdated biologics requirements, thus allowing drug manufacturers to employ new manufacturing technologies and testing capabilities. Standard preparations (standard solutions containing a precisely known concentration of an element), which help to ensure safety, purity and potency of biologics can now be obtained from sources other than FDA’s Center for Biologics Evaluation and Research (CBER), or can be developed internally by the biologics license applicant. The FDA has also removed a rule (Section 610.21 of FDA code) which specifies minimal potency limits to be met for certain antibodies and antigens. In addition, FDA is also updating regulations (Section 610.53 of FDA code) regarding storage periods and storage conditions for biologics. These amendments in regulations are expected to increase regulatory flexibility by allowing the pharmaceutical industry and the FDA to incorporate current scientific technologies in the manufacture of licensed biological products.
The early generation of biologics is losing its patent protection and are expected to face greater competition going forward from the entry of biosimilars into the market. Biosimilars are the pharmaceuticals that are developed to have similar properties to a biologic drug that has already been approved. Demand for biosimilars is being fueled by governments around the world trying to reduce healthcare costs. In India, a new biosimilar policy called the ‘Guidelines on Similar Biologics’ prepared by the Central Drugs Standard Control Organization (CSDCO) is expected to give a major boost to the Indian biosimilars industry. In the EU, a pathway for approving biosimilar medicines has existed since 2003. These less expensive alternatives increase competitiveness for the biologics market putting downward pressure on pricing and market value growth.
Technology is expected to be a continued driver of market growth during this period. An area of particular development is likely to be physiology simulation modeling. Markets such as this one will benefit from the greater efficiencies offered by developments in this area. For example, Eli Lilly and Pfizer have adopted Amazon’s Elastic Compute Cloud (EC2) platform to conduct simulation models in early drug discovery that have been operational within hours, whereas traditional models would have taken weeks to conduct simulations. The Open Innovation Drug Discovery program is another initiative by Lilly to enhance the research and development of biologics. Such technological advances are likely to reduce costs and expedite the development phase of biologics, allowing companies to launch their products early.
The global biologics market is expected to grow from $253.41 billion in 2020 to $268.51 billion in 2021 at a compound annual growth rate (CAGR) of 6%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $420.55 billion in 2025 at a CAGR of 12%.
The biologics market consists of sales of biologics and related services by entities (organizations, sole traders and partnerships) that produce biologics to treat and prevent various microbial diseases and cancers. Biological products include a wide range of products such as vaccines, allergenics, somatic cells, tissues, and recombinant therapeutic proteins. This industry includes establishments that produce products that are composed of sugars, proteins, nucleic acids, and combination of all these substances isolated from humans, animal and microorganisms or produced from biotechnology methods. Specifically, most biologic medicines are developed using recombinant DNA (rDNA) technology. The biologics market is segmented into monoclonal antibodies (mabs); therapeutic proteins; and vaccines.
North America was the largest region in the global biologics market, accounting for 53% of the market in 2020. Asia Pacific was the second largest region accounting for 21% of the global biologics market. Africa was the smallest region in the global biologics market.
The US Food and Drug Administration (FDA) has revised its regulations to eliminate outdated biologics requirements, thus allowing drug manufacturers to employ new manufacturing technologies and testing capabilities. Standard preparations (standard solutions containing a precisely known concentration of an element), which help to ensure safety, purity and potency of biologics can now be obtained from sources other than FDA’s Center for Biologics Evaluation and Research (CBER), or can be developed internally by the biologics license applicant. The FDA has also removed a rule (Section 610.21 of FDA code) which specifies minimal potency limits to be met for certain antibodies and antigens. In addition, FDA is also updating regulations (Section 610.53 of FDA code) regarding storage periods and storage conditions for biologics. These amendments in regulations are expected to increase regulatory flexibility by allowing the pharmaceutical industry and the FDA to incorporate current scientific technologies in the manufacture of licensed biological products.
The early generation of biologics is losing its patent protection and are expected to face greater competition going forward from the entry of biosimilars into the market. Biosimilars are the pharmaceuticals that are developed to have similar properties to a biologic drug that has already been approved. Demand for biosimilars is being fueled by governments around the world trying to reduce healthcare costs. In India, a new biosimilar policy called the ‘Guidelines on Similar Biologics’ prepared by the Central Drugs Standard Control Organization (CSDCO) is expected to give a major boost to the Indian biosimilars industry. In the EU, a pathway for approving biosimilar medicines has existed since 2003. These less expensive alternatives increase competitiveness for the biologics market putting downward pressure on pricing and market value growth.
Technology is expected to be a continued driver of market growth during this period. An area of particular development is likely to be physiology simulation modeling. Markets such as this one will benefit from the greater efficiencies offered by developments in this area. For example, Eli Lilly and Pfizer have adopted Amazon’s Elastic Compute Cloud (EC2) platform to conduct simulation models in early drug discovery that have been operational within hours, whereas traditional models would have taken weeks to conduct simulations. The Open Innovation Drug Discovery program is another initiative by Lilly to enhance the research and development of biologics. Such technological advances are likely to reduce costs and expedite the development phase of biologics, allowing companies to launch their products early.
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd.
- Bristol-Myers Squibb
- GlaxoSmithKline Plc.
- AbbVie
Note: Product cover images may vary from those shown
LOADING...